-
Je něco špatně v tomto záznamu ?
The European landscape on allogeneic haematopoeietic cell transplantation in Chronic Lymphocytic Leukaemia between 2009 and 2019: a perspective from the Chronic Malignancies Working Party of the EBMT
O. Tournilhac, M. van Gelder, DJ. Eikema, N. Zinger, P. Dreger, M. Bornhäuser, V. Vucinic, C. Scheid, JJ. Cornelissen, T. Schroeder, P. Jindra, H. Sengeloev, S. Nguyen Quoc, M. Stelljes, IW. Blau, J. Mayer, S. Paneesha, P. Chevallier, E. Forcade,...
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, přehledy
NLK
Free Medical Journals
od 1997 do Před 1 rokem
Freely Accessible Science Journals
od 1997 do Před 1 rokem
ProQuest Central
od 2000-01-01 do Před 1 rokem
Open Access Digital Library
od 1997-01-01
Health & Medicine (ProQuest)
od 2000-01-01 do Před 1 rokem
- MeSH
- chronická lymfatická leukemie * terapie MeSH
- COVID-19 * etiologie MeSH
- homologní transplantace metody MeSH
- lidé MeSH
- lokální recidiva nádoru MeSH
- příprava pacienta k transplantaci metody MeSH
- retrospektivní studie MeSH
- transplantace hematopoetických kmenových buněk * metody MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Allogeneic transplantation (allo-HCT) is a curative treatment in CLL whose efficacy including the most severe forms had led to the 2006 EBMT recommendations. The advent after 2014 of targeted therapies has revolutionized CLL management, allowing prolonged control to patients who have failed immunochemotherapy and/or have TP53 alterations. We analysed the pre COVID pandemic 2009-2019 EBMT registry. The yearly number of allo-HCT raised to 458 in 2011 yet dropped from 2013 onwards to an apparent plateau above 100. Within the 10 countries who were under the EMA for drug approval and performed 83.5% of those procedures, large initial differences were found but the annual number converged to 2-3 per 10 million inhabitants during the 3 most recent years suggesting that allo-HCT remains applied in selected patients. Long-term follow-up on targeted therapies shows that most patients relapse, some early, with risk factors and resistance mechanisms being described. The treatment of patients exposed to both BCL2 and BTK inhibitors and especially those with double refractory disease will become a challenge in which allo-HCT remains a solid option in competition with emerging therapies that have yet to demonstrate their long-term effectiveness.
Birmingham Heartlands Hospital Birmingham UK
Bone Marrow Transplant Unit L Copenhagen Denmark
Charles University Hospital Pilsen Czech Republic
CHU de Lille INSERM U1286 Infinite Univ Lille Lille France
Department of Haematology Trinity College Dublin St James's Hospital Dublin Ireland
EBMT Leiden Study Unit Leiden The Netherlands
EBMT Statistical Unit Leiden The Netherlands
Erasmus MC Cancer Institute Rotterdam The Netherlands
Fundació Institut d'Investigació Sanitària Illes Balears IdISBa Palma de Mallorca Spain
Hopital la Pitié Salpêtrière Universite Paris 4 Paris France
Medical Clinic and Policinic 1 Leipzig Germany
Medizinische Klinik m S Hämatologie Onkologie und Tumorimmunologie Berlin Germany
Ospedale San Gerardo Monza Italy
Programme de Transplantation and Therapie Cellulaire Marseille France
Sahlgrenska University Hospital Goeteborg Sweden
St Bartholomew's and The Royal London NHS Trust London UK
Universitaetsklinikum Dresden Dresden Germany
University College London Hospitals NHS Trust London UK
University Department of Hematology Aarhus Denmark
University Hospital Brno Brno Czech Republic
University Hospital Eppendorf Hamburg Germany
University Hospital Essen Germany
University Hospital Maastricht Maastricht The Netherlands
University of Cologne Cologne Germany
University of Heidelberg Heidelberg Germany
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23011239
- 003
- CZ-PrNML
- 005
- 20230801132911.0
- 007
- ta
- 008
- 230718s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41409-023-01955-z $2 doi
- 035 __
- $a (PubMed)36977926
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Tournilhac, Olivier $u Service d'Hematologie et de Therapie Cellulaire, CHU Estaing, EA 7453, CIC, Universite Clermont Auvergne, Clermont-Ferrand, France. otournilhac@chu-clermontferrand.fr $1 https://orcid.org/000000029438621X
- 245 14
- $a The European landscape on allogeneic haematopoeietic cell transplantation in Chronic Lymphocytic Leukaemia between 2009 and 2019: a perspective from the Chronic Malignancies Working Party of the EBMT / $c O. Tournilhac, M. van Gelder, DJ. Eikema, N. Zinger, P. Dreger, M. Bornhäuser, V. Vucinic, C. Scheid, JJ. Cornelissen, T. Schroeder, P. Jindra, H. Sengeloev, S. Nguyen Quoc, M. Stelljes, IW. Blau, J. Mayer, S. Paneesha, P. Chevallier, E. Forcade, N. Kröger, D. Blaise, J. Gribben, B. Nielsen, JE. Johansson, C. Kyriakou, Y. Beguin, P. Pioltelli, A. Sampol, DP. McLornan, J. Schetelig, PJ. Hayden, I. Yakoub-Agha
- 520 9_
- $a Allogeneic transplantation (allo-HCT) is a curative treatment in CLL whose efficacy including the most severe forms had led to the 2006 EBMT recommendations. The advent after 2014 of targeted therapies has revolutionized CLL management, allowing prolonged control to patients who have failed immunochemotherapy and/or have TP53 alterations. We analysed the pre COVID pandemic 2009-2019 EBMT registry. The yearly number of allo-HCT raised to 458 in 2011 yet dropped from 2013 onwards to an apparent plateau above 100. Within the 10 countries who were under the EMA for drug approval and performed 83.5% of those procedures, large initial differences were found but the annual number converged to 2-3 per 10 million inhabitants during the 3 most recent years suggesting that allo-HCT remains applied in selected patients. Long-term follow-up on targeted therapies shows that most patients relapse, some early, with risk factors and resistance mechanisms being described. The treatment of patients exposed to both BCL2 and BTK inhibitors and especially those with double refractory disease will become a challenge in which allo-HCT remains a solid option in competition with emerging therapies that have yet to demonstrate their long-term effectiveness.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a chronická lymfatická leukemie $x terapie $7 D015451
- 650 12
- $a transplantace hematopoetických kmenových buněk $x metody $7 D018380
- 650 _2
- $a lokální recidiva nádoru $7 D009364
- 650 12
- $a COVID-19 $x etiologie $7 D000086382
- 650 _2
- $a homologní transplantace $x metody $7 D014184
- 650 _2
- $a příprava pacienta k transplantaci $x metody $7 D019172
- 650 _2
- $a retrospektivní studie $7 D012189
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a van Gelder, Michel $u University Hospital Maastricht, Maastricht, The Netherlands
- 700 1_
- $a Eikema, Dirk-Jan $u EBMT Statistical Unit, Leiden, The Netherlands
- 700 1_
- $a Zinger, Nienke $u EBMT Leiden Study Unit, Leiden, The Netherlands
- 700 1_
- $a Dreger, Peter $u University of Heidelberg, Heidelberg, Germany $1 https://orcid.org/0000000274298570
- 700 1_
- $a Bornhäuser, Martin $u Universitaetsklinikum Dresden, Dresden, Germany
- 700 1_
- $a Vucinic, Vladan $u Medical Clinic and Policinic 1, Leipzig, Germany $1 https://orcid.org/000000028398285X
- 700 1_
- $a Scheid, Christof $u University of Cologne, Cologne, Germany
- 700 1_
- $a Cornelissen, Jan J $u Erasmus MC Cancer Institute, Rotterdam, The Netherlands
- 700 1_
- $a Schroeder, Thomas $u University Hospital, Essen, Germany
- 700 1_
- $a Jindra, Pavel $u Charles University Hospital, Pilsen, Czech Republic $1 https://orcid.org/0000000284157069
- 700 1_
- $a Sengeloev, Henrik $u Bone Marrow Transplant Unit L, Copenhagen, Denmark
- 700 1_
- $a Nguyen Quoc, Stephanie $u Hopital la Pitié-Salpêtrière, Universite Paris IV, Paris, France
- 700 1_
- $a Stelljes, Matthias $u University of Muenster, Muenster, Germany
- 700 1_
- $a Blau, Igor Wolfgang $u Medizinische Klinik m. S. Hämatologie, Onkologie und Tumorimmunologie, Berlin, Germany
- 700 1_
- $a Mayer, Jiri $u University Hospital Brno, Brno, Czech Republic
- 700 1_
- $a Paneesha, Shankara $u Birmingham Heartlands Hospital, Birmingham, UK
- 700 1_
- $a Chevallier, Patrice $u CHU Nantes, Nantes, France $1 https://orcid.org/0000000331425581
- 700 1_
- $a Forcade, Edouard $u CHU Bordeaux, Pessac, France $1 https://orcid.org/0000000288732868
- 700 1_
- $a Kröger, Nicolaus $u University Hospital Eppendorf, Hamburg, Germany $1 https://orcid.org/0000000151039966
- 700 1_
- $a Blaise, Didier $u Programme de Transplantation & Therapie Cellulaire, Marseille, France $1 https://orcid.org/0000000256849447
- 700 1_
- $a Gribben, John $u St. Bartholomew's and The Royal London NHS Trust, London, UK $1 https://orcid.org/0000000285057430 $7 xx0043894
- 700 1_
- $a Nielsen, Bendt $u University Department of Hematology, Aarhus, Denmark
- 700 1_
- $a Johansson, Jan-Erik $u Sahlgrenska University Hospital, Goeteborg, Sweden
- 700 1_
- $a Kyriakou, Charalampia $u University College London Hospitals NHS Trust, London, UK
- 700 1_
- $a Beguin, Yves $u University of Liege and CHU of Liège, Liege, Belgium
- 700 1_
- $a Pioltelli, Pietro $u Ospedale San Gerardo, Monza, Italy
- 700 1_
- $a Sampol, Antònia $u Fundació Institut d'Investigació Sanitària Illes Balears-IdISBa, Palma de Mallorca, Spain $1 https://orcid.org/0000000174656203
- 700 1_
- $a McLornan, Donal P $u University College London Hospitals NHS Trust, London, UK $1 https://orcid.org/000000031224091X
- 700 1_
- $a Schetelig, Johannes $u Universitaetsklinikum Dresden, Dresden, Germany
- 700 1_
- $a Hayden, Patrick J $u Department of Haematology, Trinity College Dublin, St. James's Hospital, Dublin, Ireland $1 https://orcid.org/0000000313744503
- 700 1_
- $a Yakoub-Agha, Ibrahim $u CHU de Lille, INSERM U1286, Infinite, Univ Lille, Lille, France $1 https://orcid.org/0000000345248782
- 773 0_
- $w MED00000834 $t Bone marrow transplantation $x 1476-5365 $g Roč. 58, č. 6 (2023), s. 621-624
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36977926 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230718 $b ABA008
- 991 __
- $a 20230801132908 $b ABA008
- 999 __
- $a ok $b bmc $g 1963563 $s 1197504
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 58 $c 6 $d 621-624 $e 20230328 $i 1476-5365 $m Bone marrow transplantation $n Bone Marrow Transplant $x MED00000834
- LZP __
- $a Pubmed-20230718
